Physician profile
Jeffrey E Taber
NPI 1861448987
$7,538.20
in general payments reported to CMS, 2019-2025
38 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $319 · 2021: $1,071 · 2022: $802 · 2023: $1,861 · 2024: $1,118 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,977 · Travel and Lodging: $698 · Education: $55.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.60 |
| Travel and Lodging | $698.32 |
| Education | $55.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,546.02 | 2019-2025 | Lithovue, Ams 700, Ams 700 Cxr Rte Kit |
| Astellas Pharma US INC | $437.05 | 2019-2023 | Myrbetriq |
| Axonics, INC. | $379.69 | 2021-2024 | Axonics |
| Urogen Pharma, INC. | $366.24 | 2021-2025 | Jelmyto |
| Calyxo, INC. | $364.57 | 2023-2025 | Cvac Aspiration System |
| Teleflex LLC | $362.47 | 2021 | |
| Sumitomo Pharma America, INC. | $305.24 | 2024-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $267.42 | 2019-2025 | Erleada |
| Abbvie INC. | $230.54 | 2020-2025 | Botox |
| Ge Healthcare | $186.01 | 2024 | |
| Olympus America INC. | $159.78 | 2025 | Itind System |
| Baxter Healthcare | $150.48 | 2025 | Starling System |
| Coloplast Corp | $137.33 | 2021 | |
| Merck Sharp & Dohme LLC | $124.55 | 2022-2025 | Keytruda, Lynparza |
| Agiliti Surgical, INC. | $123.21 | 2020-2025 | Koelis Trinity Mri/US Fusion |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $119.06 | 2023 | |
| Visionrt, INC. | $113.26 | 2025 | |
| Neotract INC. | $100.65 | 2019 | |
| Procept Biorobotics Corporation | $99.01 | 2021-2025 | Aquabeam Robotic System |
| Laborie Medical Technologies Corp. | $97.34 | 2022 | |
| Medtronic, INC. | $93.53 | 2022 | |
| Pfizer INC. | $89.05 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.06 | 2021-2023 | |
| Ambu INC. | $66.29 | 2024-2025 | |
| Telix Pharmaceuticals | $61.05 | 2023-2025 | Illuccix |
| Amgen INC. | $58.38 | 2019 | |
| Ferring Pharmaceuticals INC. | $56.06 | 2024-2025 | Adstiladrin |
| Tolmar, INC. | $55.41 | 2023 | |
| Urovant Sciences INC | $51.35 | 2022 | |
| Caldera Medical, INC | $50.71 | 2023 | Desara |
| Cardinal Health 110 LLC | $41.64 | 2023 | |
| 180 Medical, INC. | $35.80 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $32.93 | 2024 | Provenge |
| Allergan, INC. | $24.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.21 | 2025 | |
| Intuitive Surgical, INC. | $18.49 | 2024 | |
| Blue Earth Diagnostics | $16.09 | 2021 | |
| Edap Technomed INC | $11.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Taber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.